Questions Remain About HBIO s Capital Equipment Biz Despite Steps to Clarify | GenomeWeb

Faced with a stagnant stock price that has hovered in the $3 to $5 range over the past year and investors whose patience may be "wearing a bit thin," Harvard Bioscience held a conference call last week to provide a more complete picture of its two major business segments and how it intends to grow them.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genetic history of HIV in the US, and more.

There are a few projects aimed at addressing the lack of diversity in genomic research, Technology Review reports.

A national assessment shows that US students lag in the sciences, but suggests that achievement gaps are narrowing.

Harvard's George Church discusses HGP-write with the Journal of the American Medical Association.